Details for Patent: 10,154,963

✉ Email this page to a colleague

Which drugs does patent 10,154,963 protect, and when does it expire?

Patent 10,154,963 protects SOAANZ and is included in one NDA.

This patent has two patent family members in two countries.

Summary for Patent: 10,154,963

Title:	Controlled-release formulations comprising Torsemide
Abstract:	Disclosed herein are controlled-release (GR, e.g., extended-release (ER) or prolonged-release (PR)) oral dosage formulation comprising an effective amount of Torsemide or a pharmaceutically acceptable salt thereof and at least one sustained release excipient comprising a polymer, wherein the at least one matrix component is selected from the group consisting of: hydroxy propyl cellulose (HPC), hydroxpropyl methyl cellulose (HPMC), glyceryl behenate, and a polyethylene glycol glyceride. Torsemide may be present in the formulation in a range of about 1 wt % to about 20 wt %, or about 5 wt % to about 10 wt % and the matrix component is present in the formulation in a range of about 5 wt % to about 50 wt %, or about 15 wt % to about 35 wt %. The formulation may further comprise at least one binder, lactose, talc and magnesium stearate. Methods of making and using the controlled-release oral dosage Torsemide formulation are also disclosed. A novel mechanism for Torsemide action in diuresis is further disclosed.
Inventor(s):	Shah; Salim (Vienna, VA)
Assignee:	SARFEZ PHARMACEUTICALS, INC. (Vienna, VA)
Application Number:	15/027,355
Patent Claim Types: see list of patent claims	Use; Formulation; Compound; Delivery; Dosage form;

Drugs Protected by US Patent 10,154,963

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Sarfe Pharms	SOAANZ	torsemide	TABLET;ORAL	213218-001	Jun 14, 2021		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up	Y				⤷ Sign Up
Sarfe Pharms	SOAANZ	torsemide	TABLET;ORAL	213218-002	Jun 14, 2021		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up	Y				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 10,154,963

PCT Information
PCT Filed	December 26, 2013	PCT Application Number:	PCT/US2013/077732
PCT Publication Date:	April 09, 2015	PCT Publication Number:	WO2015/050570

International Family Members for US Patent 10,154,963

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	3065718	⤷ Sign Up
World Intellectual Property Organization (WIPO)	2015050570	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.